Edesa Biotech Inc (EDSA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Edesa Biotech Inc stock (EDSA) is currently trading at $7.02. Edesa Biotech Inc PS ratio (Price-to-Sales) is 120477.93. Analyst consensus price target for EDSA is $11.00. WallStSmart rates EDSA as Sell.
- EDSA PE ratio analysis and historical PE chart
- EDSA PS ratio (Price-to-Sales) history and trend
- EDSA intrinsic value — DCF, Graham Number, EPV models
- EDSA stock price prediction 2025 2026 2027 2028 2029 2030
- EDSA fair value vs current price
- EDSA insider transactions and insider buying
- Is EDSA undervalued or overvalued?
- Edesa Biotech Inc financial analysis — revenue, earnings, cash flow
- EDSA Piotroski F-Score and Altman Z-Score
- EDSA analyst price target and Smart Rating
Edesa Biotech Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Edesa Biotech Inc (EDSA) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Edesa Biotech Inc (EDSA) Key Strengths (1)
52.18% held by institutions, strong professional interest
Supporting Valuation Data
Edesa Biotech Inc (EDSA) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -99.90%, a shrinking business
Very expensive at 120477.9x annual revenue
Very expensive at 13.2x book value
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Edesa Biotech Inc (EDSA) Detailed Analysis Report
Overall Assessment
This company scores 13/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (120477.93), Price/Book (13.18) suggest expensive pricing. Growth concerns include Revenue Growth at -99.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -96.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -96.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -99.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EDSA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EDSA's Price-to-Sales ratio of 120477.93x trades 1007% above its historical average of 10880.82x (91th percentile), historically expensive. The current valuation is 0% below its historical high of 120477.93x set in Feb 2026, and 1617053% above its historical low of 7.45x in Sep 2017.
WallStSmart Analysis Synopsis
Data-driven financial summary for Edesa Biotech Inc (EDSA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Edesa Biotech Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 500 with 100% decline year-over-year.
Key Findings
Spending 224945% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Edesa Biotech Inc.
Bottom Line
Edesa Biotech Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Edesa Biotech Inc(EDSA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, is engaged in the research and development, manufacture and marketing of pharmaceuticals for inflammatory and immune-related diseases. The company is headquartered in Markham, Canada.